Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC) research hub

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

This Phase 2 clinical trial is testing a new targeted medicine called patritumab deruxtecan for adults with advanced non-small cell lung cancer. It is designed for people whose cancer has a specific gene change (an EGFR mutation) and has stopped responding to previous cancer treatments.